Travere Therapeutics, Inc. (TVTX) SEC Filings — 2025
13 SEC filings for Travere Therapeutics, Inc. (TVTX) in 2025.
Filings
- Travere Therapeutics Swings to Profit on Soaring FILSPARI Sales — 10-Q · Oct 30, 2025
- Travere Therapeutics Relocates Principal Executive Offices — 8-K · Sep 10, 2025
- Travere Therapeutics Posts Strong Q2 Revenue Growth, Up 5.5% — 10-Q · Aug 6, 2025
- Travere Therapeutics Announces Board Changes and Officer Appointments — 8-K · May 16, 2025
- Travere Therapeutics Files 8-K, Changes Principal Office — 8-K · May 15, 2025
- Travere Therapeutics Q1 2025 10-Q Filed — 10-Q · May 1, 2025
- Travere Therapeutics Appoints New Chief Medical Officer — 8-K · Apr 30, 2025
- Travere Therapeutics 2024 Executive Compensation Details — DEF 14A · Apr 1, 2025
- Travere Therapeutics Files 8-K, Updates Corporate Address — 8-K · Mar 17, 2025
- Travere Therapeutics Files 2024 10-K — 10-K · Feb 21, 2025
- Travere Therapeutics Files 8-K on Operations and Financials — 8-K · Feb 20, 2025
- Travere Therapeutics Files 8-K — 8-K · Feb 11, 2025
- Travere Therapeutics Files 8-K on Financials — 8-K · Jan 13, 2025